Human RCTPubMed ID: 27199432·2016

Semaglutide and Atherosclerosis Progression in Type 2 Diabetes

Marso SP, Bain SC, Consoli A, et al.

New England Journal of Medicine, 2016 · n = 7026

Key finding

Semaglutide reduced major adverse cardiovascular events by 26% (HR 0.74, 95% CI 0.58-0.95), death by 39%, and slowed albuminuria progression.

Summary

LEADER trial demonstrating cardiovascular and renal protective effects of semaglutide in type 2 diabetes with established CVD.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT